Senescent cells are damaged cells that have stopped dividing. They secrete a cocktail of inflammatory signals — the senescence-associated secretory phenotype, or SASP — that recruits immune cells, promotes inflammation, and degrades surrounding tissue. Accumulation of senescent cells is a hallmark of aging. The therapeutic strategy is obvious: kill the senescent cells (senolytics) or suppress their secretions (senomorphics). Remove the damage, restore the tissue.

Except the same SASP that degrades tissue also promotes regeneration. The inflammatory cytokines — particularly IL-6 — act on neighboring cells in a paracrine loop that enhances cellular reprogramming. Cells adjacent to senescent cells are pushed toward a more plastic, stem-like state. The damage signal is also the repair signal. The senescent cell, through its secretions, creates a niche in which tissue regeneration is more likely.

The paradox resolves into a timing problem. In the short term, SASP promotes repair by stimulating reprogramming in neighbors. In the long term, accumulated SASP drives chronic inflammation, fibrosis, and tissue degradation. The same molecule does both — the difference is duration. A pulse of IL-6 is a repair signal. A sustained elevation of IL-6 is a disease state. The molecule has no intrinsic meaning; its effect depends on temporal context.

The through-claim: damage and repair are not opposite states but overlapping processes that share molecular machinery. The cell that has stopped contributing to the tissue directly (it no longer divides) contributes indirectly by creating an environment that promotes renewal in its neighbors. The cost of removing senescent cells indiscriminately is losing the regenerative niche they provide. The cost of keeping them is chronic inflammation. The therapeutic window — the intervention that removes the chronic signal while preserving the acute one — requires temporal precision, not just molecular targeting.

Age is the accumulation of repair signals that outlasted their usefulness.